On 3 September 2026, Beijing Easeng Medical Technology Co., Ltd., the First Affiliated Hospital of Xiamen University and the Xiamen Cell Therapy Research Center held the closing meeting for a dry-eye investigational drug study in Xiamen. The teams reviewed the study, its interim findings and the proposed next steps for translation.
Clinical collaboration
The investigator-initiated exploratory study examined eye drops containing small extracellular vesicles derived from human umbilical-cord mesenchymal stem cells for dry eye. Easeng Medical presented the project’s progress and discussed the compliant translation of research outcomes with its clinical and research partners.
Study status
The study was exploratory and intended to provide a preliminary assessment of the research approach’s safety and efficacy. Completion of this stage does not mean that the product has received marketing approval.
Next steps
Easeng Medical plans to use the study findings to refine its development and quality work and to advance subsequent clinical and registration activities in accordance with applicable requirements. Beijing Easeng Medical Technology Co., Ltd. is part of Beijing Easeng Holdings Co., Ltd.
This article is a website summary of information previously published through the company’s official WeChat account. Regulatory approvals and subsequent formal disclosures shall prevail.